Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
116. |
ECCT/23/08/01 | ARNASA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Dr Teresa Kinyari Site(s) in Kenya 1. University of Nairobi Clinical Research Centre (Nairobi City county) 2. Center for Research In Tropical Medicine and Community Development (Nairobi City county) 3. Clinical Research Health Network (CREA-N) (Machakos county) 4. KEMRI-CRDR Siaya Clinical Research Annex (Siaya county) 5. KEMRI-Mtwapa Clinical Annex (Kilifi county) 6. KEMRI-CRDR Clinical Research Annex (Nairobi City county) |
View |
117. |
ECCT/24/03/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Prof Walter Godfrey Jaoko Site(s) in Kenya 1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
View |
118. |
ECCT/24/04/08 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Wilson Muraya Site(s) in Kenya 1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county) |
View |
119. |
ECCT/24/05/01 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Dr Videlis Nduba Site(s) in Kenya 1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county) |
View |
120. |
ECCT/24/05/02 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Jacqueline Mirera Site(s) in Kenya 1. Clinical Research Health Network (CREA-N), Machakos Level 5 Hospital Site (Machakos county) |
View |